ASCC3

Across TCGA pan-cancer cohorts, ASCC3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ASCC3 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ASCC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ASCC3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and GBM are the cancer types where ASCC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.736	0.536	.006	15	view →
PDAC	DFS	Median	II,III,IV	0.696	0.808	.023	7	view →
GBM	DFS	Quartile	All	0.205	0.463	.004	6	view →
LUAD	OS	Median	III,IV	1.000	0.663	.007	5	view →
UCEC	OS	Tertile	All	1.000	0.879	.013	4	view →
LSCC	DFS	Median	All	0.888	0.482	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ASCC3–HNSC (DFS)

Open the HNSC breakdown →